Insider · CIK 0001511034
Sandesh Mahatme
Files at CRSP (CRISPR Therapeutics AG), VOR (Vor Biopharma Inc.). First filing -, latest -.
Sandesh Mahatme files SEC Form 4 as director and CFO at CRSP (CRISPR Therapeutics AG), and also at VOR (Vor Biopharma Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sandesh Mahatme has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | CRSP CRISPR Therapeutics AG | AGrant or award Stock Option (Right to Buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jun 9, 2026 |
| Dec 5, 2025 | VOR Vor Biopharma Inc. | DDisposition to issuer Common Stock | -694,137 | $0.00 | $0 | 0 | Dec 9, 2025 |
| Dec 5, 2025 | VOR Vor Biopharma Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +1,388,274 | $0.00 | $0 | 1,388,274 | Dec 9, 2025 |
| Jul 9, 2025 | VOR Vor Biopharma Inc. | AGrant or award Common Stock | +13,882,750 | $0.00 | $0 | 13,882,750 | Jul 10, 2025 |
| Jun 5, 2025 | CRSP CRISPR Therapeutics AG | AGrant or award Stock Option (Right to Buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jun 6, 2025 |
Questions about Sandesh Mahatme
Answered from the filings on this page, as of the latest one.
Is Sandesh Mahatme buying or selling?
Sandesh Mahatme has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sandesh Mahatme's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sandesh Mahatme has 0.
Where does Sandesh Mahatme file Form 4?
Sandesh Mahatme has filed Form 4 at CRSP (CRISPR Therapeutics AG); VOR (Vor Biopharma Inc.) as CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.